News MSD joins PD-1/VEGF push in cancer with LaNova deal There has been a lot of talk about drugs targeting both PD-1 and VEGF stealing the crown held by MSD's Keytruda in cancer immunotherapy.
Sales & Marketing Sponsored Enabling site success: Key insights to reducing burden and i... Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.
